Suppr超能文献

转移性脊柱癌患者的预后因素及其预测价值

Prognostic factors and its predictive value in patients with metastatic spinal cancer.

作者信息

Gao Qing-Peng, Yang Da-Zhi, Yuan Zheng-Bin, Guo Yu-Xia

机构信息

Department of Spine Surgery, The Second Clinical Medical College of Jinan University, Shenzhen 518020, Guangdong Province, China.

Department of Spine Surgery, Shenzhen People's Hospital, 2 Clinical Medical College of Jinan University, Shenzhen 518020, Guangdong Province, China.

出版信息

World J Clin Cases. 2021 Jul 16;9(20):5470-5478. doi: 10.12998/wjcc.v9.i20.5470.

Abstract

BACKGROUND

The spine is the most common location of metastatic diseases. Treating a metastatic spinal tumor depends on many factors, including patients' overall health and life expectancy. The present study was conducted to investigate prognostic factors and clinical outcomes in patients with vertebral metastases.

AIM

To investigate prognostic factors and their predictive value in patients with metastatic spinal cancer.

METHODS

A retrospective analysis of 109 patients with metastatic spinal cancer was conducted between January 2015 and September 2017. The prognoses and survival were analyzed, and the effects of factors such as clinical features, treatment methods, primary lesions and affected spinal segments on the prognosis of patients with metastatic spinal cancer were discussed. The prognostic value of Frankel spinal cord injury functional classification scale, metastatic spinal cord compression (MSCC), spinal instability neoplastic score (SINS) and the revised Tokuhashi score for prediction of prognosis was explored in patients with metastatic spinal tumors.

RESULTS

Age, comorbidity of metastasis from elsewhere, treatment methods, the number of spinal tumors, patient's attitude toward tumors and Karnofsky performance scale score have an effect on the prognosis of patients (all < 0.05). With respect to classification of spinal cord injury, before operation, the proportion of grade B and grade C was higher in the group of patients who died than in the group of patients who survived, and that of grade D and grade E was lower in the group of patients who died than in the group of patients who survived (all < 0.05). At 1 mo after operation, the proportion of grade A, B and C was higher in the group of patients who died than in the group of patients who survived, and that of grade E was lower in patients in the group of patients who died than in the group of patients who survived (all < 0.05). MSCC occurred in four (14.3%) patients in the survival group and 17 (21.0%) patients in the death group ( < 0.05). All patients suffered from intractable pain, dysfunction in spinal cord and even paralysis. The proportion of SINS score of 1 to 6 points was lower in the death group than in the survival group, and the proportion of SINS score of 7 to 12 points was higher in the death group than in the survival group (all < 0.05). The proportion of revised Tokuhashi score of 0 to 8 points and 9 to 11 points were higher in the death group than in the survival group, and the proportion of revised Tokuhashi score of 12 to 15 points was lower in the death group than in the survival group (all < 0.05). Frankel spinal cord injury functional classification scale, MSCC, SINS and revised Tokuhashi score were important factors influencing the surgical treatment of patients with metastatic spinal cancer (all < 0.05).

CONCLUSION

Frankel spinal cord injury functional classification scale, MSCC, SINS and revised Tokuhashi score were helpful in predicting the prognosis of patients with metastatic spinal cancer.

摘要

背景

脊柱是转移性疾病最常见的发病部位。治疗转移性脊柱肿瘤取决于多种因素,包括患者的整体健康状况和预期寿命。本研究旨在调查椎体转移患者的预后因素及临床结局。

目的

探讨转移性脊柱癌患者的预后因素及其预测价值。

方法

对2015年1月至2017年9月期间109例转移性脊柱癌患者进行回顾性分析。分析患者的预后及生存情况,探讨临床特征、治疗方法、原发病变及受累脊柱节段等因素对转移性脊柱癌患者预后的影响。探讨Frankel脊髓损伤功能分级量表、转移性脊髓压迫(MSCC)、脊柱不稳定肿瘤评分(SINS)及修订的Tokuhashi评分对转移性脊柱肿瘤患者预后预测的价值。

结果

年龄、其他部位转移的合并症、治疗方法、脊柱肿瘤数量、患者对肿瘤的态度及卡氏功能状态评分对患者预后有影响(均P<0.05)。在脊髓损伤分级方面,术前死亡组患者中B级和C级的比例高于存活组,D级和E级的比例低于存活组(均P<0.05)。术后1个月,死亡组患者中A级、B级和C级的比例高于存活组,E级的比例低于存活组(均P<0.05)。存活组有4例(14.3%)患者发生MSCC,死亡组有17例(21.0%)患者发生MSCC(P<0.05)。所有患者均有顽固性疼痛、脊髓功能障碍甚至瘫痪。死亡组SINS评分为1至6分的比例低于存活组,SINS评分为7至12分的比例高于存活组(均P<0.05)。死亡组修订的Tokuhashi评分为0至8分和9至11分的比例高于存活组,修订的Tokuhashi评分为12至15分的比例低于存活组(均P<0.05)。Frankel脊髓损伤功能分级量表、MSCC、SINS及修订的Tokuhashi评分是影响转移性脊柱癌患者手术治疗的重要因素(均P<0.05)。

结论

Frankel脊髓损伤功能分级量表、MSCC、SINS及修订的Tokuhashi评分有助于预测转移性脊柱癌患者的预后。

相似文献

1
Prognostic factors and its predictive value in patients with metastatic spinal cancer.
World J Clin Cases. 2021 Jul 16;9(20):5470-5478. doi: 10.12998/wjcc.v9.i20.5470.
2
Accuracy of the revised Tokuhashi score in predicting survival in patients with metastatic spinal cord compression (MSCC).
Eur Spine J. 2013 Mar;22 Suppl 1(Suppl 1):S21-6. doi: 10.1007/s00586-012-2649-5. Epub 2013 Jan 18.
3
The surgical management of metastatic spinal tumors based on an Epidural Spinal Cord Compression (ESCC) scale.
Spine J. 2015 Aug 1;15(8):1738-43. doi: 10.1016/j.spinee.2015.03.040. Epub 2015 Mar 27.
5
Metastatic spinal cord compression (MSCC) treated with palliative decompression: Surgical timing and survival rate.
PLoS One. 2017 Dec 29;12(12):e0190342. doi: 10.1371/journal.pone.0190342. eCollection 2017.
8
Reassessment of scoring systems and prognostic factors for metastatic spinal cord compression.
Spine J. 2015 May 1;15(5):944-50. doi: 10.1016/j.spinee.2013.06.036. Epub 2013 Oct 9.
9
Comparative Study of Circumferential Decompression and Posterior Decompression in Palliative Surgery for Metastatic Thoracic Spinal Tumors.
Clin Spine Surg. 2022 Nov 1;35(9):E685-E692. doi: 10.1097/BSD.0000000000001342. Epub 2022 May 9.
10
Optimization of the Revised Tokuhashi Scoring System: New Prognostic Criteria for Metastatic Spinal Tumor in Surgical Cases.
Spine Surg Relat Res. 2020 Aug 31;5(2):81-85. doi: 10.22603/ssrr.2020-0102. eCollection 2021.

引用本文的文献

1
Integrated management of metastatic spinal tumors: current status and future directions.
Med Oncol. 2025 May 14;42(6):210. doi: 10.1007/s12032-025-02764-8.
3
I brachytherapy: a useful treatment to control painful osteoblastic bone metastases.
Clin Transl Oncol. 2023 May;25(5):1297-1306. doi: 10.1007/s12094-022-03025-0. Epub 2022 Dec 6.

本文引用的文献

2
Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy.
Clin Lung Cancer. 2021 Jan;22(1):58-66.e3. doi: 10.1016/j.cllc.2020.10.017. Epub 2020 Nov 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验